Delivery Order SPE2DB20D6035-SPE2DB24FD2BJ
- Not listed
- The U.S. Defense Logistics Agency (DLA) has awarded a $14,529.29 Firm Fixed Price Delivery Order contract to the Corporate Office division of Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. This contract is for the delivery of 4564389608 - CYCLOSPORINE 0.05% EYE EMULS 60S, with a completion date of April 25, 2024. The award is not associated with any set-aside program. Amerisourcebergen is a major supplier of pharmaceutical products and medical supplies to federal...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for CYCLOSPORINE 0.05% EYE EMULS 60S. The delivery order has a potential value of $7,335.36 and a completion date of February 12, 2024. Amerisourcebergen Drug Corp is the prime contractor and serves as a supplier of pharmaceuticals and medical supplies to U.S. government agencies, particularly the Department of Defense. The contract does...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order for $2,092.92 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to supply Cyclosporine 0.05% eye emulsion. This award has a completion date of March 6, 2024 and is not set aside. Amerisourcebergen Drug Corp holds an indefinite delivery contract (IDC) with DLA, valued up to $999,999,999.00 through December 2025, which serves as the primary vehicle for the company to deliver pharmaceutical...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corporation's Corporate Office division. The $1,324.86 firm fixed price contract is for the supply of Cyclosporine 0.05% eye emulsion, a pharmaceutical product. The contract has an ultimate completion date of August 27, 2024. Amerisourcebergen is one of the largest pharmaceutical distributors in the United States and has been awarded numerous federal contracts by various defense and civilian agencies...
- This federal contract award, valued at $5,155.02, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp's Corporate Office Division for the delivery of CYCLOSPORINE 0.05% EYE EMULS 60S. The contract is a Firm Fixed Price Delivery Order, with a completion date of July 10, 2024. Amerisourcebergen, a major pharmaceutical distribution company, holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide Cyclosporine 0.05% eye emulsion in 30-count packages. The $1,107.10 contract has a completion date of February 20, 2024. Amerisourcebergen Drug Corp, a for-profit organization, serves as a prime contractor providing pharmaceutical products and medical supplies to U.S. government agencies, particularly the Department of...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp's Corporate Office Division. The $8,960.66 delivery order is for the supply of Cyclosporine 0.05% eye emulsion, a pharmaceutical product used to treat various eye conditions. The contract has an ultimate completion date of August 13, 2024 and utilizes a Firm Fixed Price pricing structure. Amerisourcebergen, a major pharmaceutical distributor in the United States,...
- The Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of Cyclosporine 0.05% eye emulsion medication. The contract has a potential value of $1,954.08 and a performance period through February 9, 2024. Amerisourcebergen Drug Corp is the prime contractor on this delivery order, which is part of a larger indefinite delivery contract (IDC) with DLA Troop Support Medical...
- This federal contract award was issued by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office division. The $3,840.12 firm fixed price delivery order is for the supply of 4564960790 - CYCLOSPORINE 0.05% EYE EMULS 30S, with a completion date of June 21, 2024. Amerisourcebergen, a major pharmaceutical distribution company, holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued up to...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,514.41 firm fixed-price delivery order is for the supply of 4566746620 ! CYCLOSPORINE 0.05% EYE EMULS 30S, and has an ultimate completion date of December 18, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
- SPE2DB20D6035Indefinite Delivery Contract
- SPE2DB20D6035-SPE2DB24FD2BJDelivery Order
The U.S. Defense Logistics Agency (DLA) awarded a $1,072.71 Firm Fixed Price delivery order contract to Amerisourcebergen Drug Corp's Corporate Office Division for the provision of 4564366186 - CYCLOSPORINE 0.05% EYE EMULS 30S. This contract has an ultimate completion date of April 24, 2024 and was awarded on April 23, 2024. Amerisourcebergen Drug Corp is a major pharmaceutical supplier to the U.S. federal government, particularly the Department of Defense (DoD) and Department of Veterans Affairs (VA) healthcare systems. The company holds a single-award Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for Amerisourcebergen to deliver a wide range of pharmaceutical products and medical supplies to DLA facilities supporting the DoD worldwide. Additionally, Amerisourcebergen has a smaller IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs, valued up to $750,000 through May 2024.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 4/23/24 |